2026-10-30 11:00:09 UTC#545029newconfirmednews
JAZZ stock news
JAZZ stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-26 20:50:29 UTC#517286newconfirmednews
Jazz Pharmaceuticals reports $755M IPR&D charge in Q3 2026 results
2026-10-21 16:40:00 UTC#494462newconfirmednews
Morgan Stanley maintains Jazz Pharmaceuticals at Overweight, cuts price target to $314 from $322
2026-10-19 20:15:00 UTC#482858newconfirmedpress release
Jazz Pharmaceuticals to report Q3 2026 financial results on November 2, 2026
2026-10-15 16:31:49 UTC#467229newconfirmednews
Unifor members at Jazz Aviation ratify four-year contract with 21% wage increase
2026-10-13 15:55:48 UTC#453575newconfirmednews
Implanet 9M 2026 revenue grows 21% to €10.6M, driven by US expansion and JSS system sales
2026-10-09 18:55:24 UTC#440171newconfirmednews
Jazz Aviation LP crew schedulers ratify four-year labor agreement with Unifor 2002
2026-10-09 13:03:00 UTC#438482newconfirmednews
Jazz Pharmaceuticals CCO Samantha Pearce to retire by June 30, 2027
2026-10-08 14:59:00 UTC#433337newconfirmednews
RBC Capital maintains Jazz Pharmaceuticals at Outperform, cuts price target to $296 from $299
2026-10-08 10:30:00 UTC#431376newconfirmednews
PCPG Market Forecast to Reach $670M by 2036 at 7.3% CAGR, ResearchAndMarkets Reports
yahooimportance 0.30trust 0.50Merck & Co., Inc. +0.30Novartis AG +0.20Jazz Pharmaceuticals plc +0.20+2 entities
2026-09-30 17:47:01 UTC#393501duplicateconfirmednews
Citigroup initiates Buy ratings on Nuvation Bio and Jazz Pharmaceuticals
seeking alphaimportance 0.30trust 0.70Nuvation Bio Inc. +0.40Jazz Pharmaceuticals plc +0.40Citigroup Inc. +0.20
2026-09-30 12:03:00 UTC#391185newconfirmednews
Citigroup Initiates Coverage of Jazz Pharmaceuticals with Buy Rating
2026-09-24 13:15:00 UTC#362803newconfirmednews
Goldman Sachs sets $337.00 price target on Jazz Pharmaceuticals (JAZZ)
2026-09-23 21:23:16 UTC#358684newconfirmednews
Jazz Pharmaceuticals amends credit agreement, borrows $273.31M in additional Tranche B-3 term loans
2026-09-16 14:16:31 UTC#321292duplicateconfirmednews
Jazz Pharmaceuticals updates on zanidatamab oncology progress, epilepsy pipeline, and Xywav performance
quartrimportance 0.30trust 0.50Jazz Pharmaceuticals plc +0.40Zanidatamab +0.50Xywav +0.30+1 entities
2026-09-15 18:13:38 UTC#316044duplicateconfirmednews
Jazz Pharmaceuticals oncology revenue grows 32%, raises zanidatamab peak sales guidance to $3-5 billion
2026-09-15 17:31:37 UTC#315832newconfirmednews
Jazz Pharmaceuticals reports 32% oncology revenue growth, raises peak sales guidance for zanidatamab and XYWAV
2026-09-15 13:00:00 UTC#314019duplicateconfirmednews
Jazz Pharmaceuticals completes $820M acquisition of Actio Biosciences and its epilepsy candidate ABS-1230
tradingviewimportance 0.40trust 0.70Jazz Pharmaceuticals plc +0.20Actio Biosciences +0.20ABS-1230 +0.30
2026-09-15 13:00:00 UTC#314018duplicateconfirmedpress release
Jazz Pharmaceuticals completes $820 million acquisition of Actio Biosciences
pr_newswireimportance 0.40trust 1.00Jazz Pharmaceuticals plc +0.30Actio Biosciences, Inc. -0.20ABS-1230 +0.40+2 entities
2026-09-15 13:00:00 UTC#314017newconfirmednews